44 Stocks Moving in Wednesday's Pre-Market Session

Gainers

• Superconductor Technologies Inc SCON rose 45.8% to $0.35 in pre-market trading after declining 7% on Tuesday. Superconductor Technologies issued a letter to stockholders.
• Trillium Therapeutics Inc. TRIL rose 37.4% to $13.00 in pre-market trading after the company announced an update for data from its ongoing TTI-622 and TTI-621 dose escalation studies. Trillium Therapeutics also disclosed a $25 million equity investment from Pfizer.
• Watford Holdings Ltd. WTRE rose 31.5% to $23.50 in pre-market trading after Reuters reported that a consortium led by Arch Capital Group made an offer worth $500 million to acquire Watford.
• Comstock Mining Inc. LODE rose 19.8% to $1.27 in pre-market trading after the company entered into a Mineral Exploration and Mining Lease Agreement with the Sutro Tunnel Company.
• RAVE Restaurant Group, Inc. RAVE shares rose 15.9% to $0.58 in pre-market trading after climbing around 11% on Tuesday. Rave Restaurant Group's Pizza Inn, last month, partnered with RetailStack for point of sale system.
• Predictive Oncology Inc. POAI rose 11.2% to $0.9730 in pre-market trading.
• Hermitage Offshore Services Ltd. PSV rose 10.6% to $0.3980 in pre-market trading after dipping around 44% on Tuesday. Hermitage Offshore Services recently announced appeal of NYSE delisting determination.
• Antero Resources Corporation AR rose 10.7% to $3.01 in pre-market trading after declining over 7% on Tuesday.
• Moxian, Inc. MOXC shares rose 8.4% to $2.45 in pre-market trading. Moxian, last week, reported a share exchange deal with Btab Group.
• iBio, Inc. IBIO rose 8.2% to $2.05 in pre-market trading. iBio recently announced it entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc.
• Phreesia Inc PHR rose 7.9% to $32.85 in pre-market trading after reporting Q2 results.
• 9F Inc. JFU rose 7.4% to $1.30 in pre-market trading after declining over 3% on Tuesday.
• Novavax, Inc. NVAX rose 7.4% to $91.60 in pre-market trading. Novavax shares fell over 8% on Tuesday after several drug companies, including Novavax, signed a pledge committing to not file for approval of a COVID-19 vaccine until late-stage studies demonstrate safety and efficacy.
• AIM ImmunoTech Inc. AIM rose 7.4% to $2.04 in pre-market trading after gaining over 7% on Tuesday. AIM ImmunoTech recently said it decreased SARS-CoV-2 infectious viral yields by 90% using new in vitro model.
• Tesla, Inc. TSLA shares rose 7.2% to $354.01 in pre-market trading. Tesla shares fell over 21% on Tuesday, marking the worst day of declines for the automaker, after it was left out of the prestigious S&P 500 index.
• Ocugen, Inc. OCGN rose 6.5% to $0.3461 in pre-market trading. Ocugen reported that the Nasdaq has granted the company 180-day extension to regain compliance with bid price rule.
• Inovio Pharmaceuticals, Inc. INO rose 6.2% to $10.20 in pre-market trading. Inovio Pharmaceuticals, yesterday, reported a coronavirus vaccine manufacturing agreement with Thermo Fisher.
• Precipio, Inc. PRPO rose 6% to $2.50 in pre-market trading after gaining over 9% on Tuesday. Precipio is expected to host a shareholder call to discuss its COVID-19 progress and future plans today.
• Kamada Ltd. KMDA rose 5.7% to $9.70 in pre-market trading after the company received a $10.6 million missile fuze systems order. Kamada shares gained around 5% on Tuesday after the company announced the completion of enrollment and initial interim results from its Phase 1/2 clinical trial in Israel for the Plasma-derived Hyperimmune Immunoglobulin products as a potential treatment of coronavirus.
• Vaxart, Inc. VXRT rose 5.6% to $5.09 in pre-market trading. Vaxart yesterday announced its oral COVID-19 vaccine candidate induces potent systemic and mucosal immune response in preclinical studies.
• Workhorse Group Inc. WKHS rose 5.5% to $22.55 in pre-market trading after gaining over 8% on Tuesday. Workhorse recently announced agreements with Hitachi to support higher production. Hitachi will review Workhorse's operations and provide recommendations to support increased production requirements.
• Nikola Corporation NKLA rose 5.3% to $52.70 in pre-market trading. Nikola shares jumped around 41% on Tuesday after the company announced a strategic partnership with General Motors.
• Chembio Diagnostics, Inc. CEMI rose 5.3% to $4.00 in pre-market trading after the company submitted EUA application for new DPP SARS-CoV-2 IgM/IgG test system.
• Qiagen NV QGEN rose 3.5% to $49.91 in pre-market trading after the company announced the launch of its rapid portable test that can analyze 30+ samples per hour for Coronavirus antigen.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Check out these big penny stock gainers and losers

Losers

• Shiloh Industries, Inc. SHLO fell 24% to $0.5322 in pre-market trading. Shiloh Industries, last week, received court approval of "First Day" motions to support business operations..
• Slack Technologies, Inc. WORK fell 16.5% to $24.50 in pre-market trading. Slack reported upbeat earnings and sales for the second quarter. However, the company’s billing growth slowed in the quarter.
• SeaChange International Inc SEAC fell 11.9% to $1.18 in pre-market trading after the company reported downbeat Q2 results.
• Gevo, Inc. GEVO shares fell 10.6% to $0.93 in pre-market trading. Gevo shares tumbled over 10% on Tues after the company issued a business update.
• NextDecade Corporation NEXT shares fell 10.3% to $2.09 in pre-market trading after jumping over 75% on Tuesday.
• Tiffany & Co. TIF fell 10.1% to $109.50 in pre-market trading. Tiffany filed a lawsuit against LVMH to enforce merger agreement. Tiffany Files Lawsuit Against LVMH To Enforce Merger Agreement
• Athenex Inc ATNX fell 9.4% to $13.00 in pre-market trading after the company reported a 10 million share offering.
• Altimmune, Inc ALT shares fell 8.1% to $11.62 in pre-market trading. Altimmune, last week, announced completion of multiple dose toxicity and toxicokinetic studies of ALT-801.
• Luby's, Inc. LUB fell 7.7% to $2.05 in pre-market trading. Luby's shares climbed 111% on Tuesday after the company’s board adopted plan of liquidation and dissolution.
• Check-Cap Ltd. CHEK fell 7.5% to $0.36 in pre-market trading after reporting a 25.9 million share common stock offering.
• Globus Maritime Limited GLBS fell 5.9% to $0.11 in pre-market trading after declining over 4% on Tuesday.
• SRAX, Inc. SRAX fell 5.4% to $2.91 in pre-market trading after rising around 8% on Tuesday. SRAX announced plans to acquire LD Micro.
• SCWorx Corp. WORX fell 5.4% to $1.76 in pre-market trading after jumping over 22% on Tuesday.
• Vroom Inc VRM fell 5.3% to $53.25 in pre-market trading. Vroom, raised its guidance for the third quarter. However, the company’s latest forecast was still below analysts’ expectations. Vroom also disclosed a 10.35 million share common stock offering.
• Seritage Growth Properties SRG fell 5.2% to $14.85 in pre-market trading.
• Blink Charging Co. BLNK fell 5.1% to $6.13 in pre-market trading. Blink Charging recently received over $1 million follow-on order from InterEnergy for EV charging equipment for deployment in The Dominican Republic.
• Lululemon Athletica Inc. LULU fell 4.8% to $332.99 in pre-market trading. Lululemon reported better-than-expected results for its second quarter. Sales at company-owned stores declined 51% year over year to $287.2 million, while direct-to-consumer sales surged 155% to $554.3 million.
• T2 Biosystems, Inc. TTOO fell 4.8% to $1.20 in pre-market trading. T2 Biosystems, last week, announced CMS approval of new technology add-on payment for the T2Bacteria panel.
• Casey's General Stores Inc. CASY fell 4.7% to $166.00 in pre-market trading. Casey's reported upbeat earnings for its first quarter, while sales were slightly below estimates.
• Albireo Pharma Inc ALBO shares fell 4.1% to $38.00 in pre-market trading after the company reported a 3 million share offering. Albireo Pharma shares jumped 45% on Tuesday after the company disclosed that its Phase 3 trial of odevixibat met both primary endpoints.